On 2 March 2021 the Government announced that it had commissioned a review of the Pharmaceutical Management Agency, known as PHARMAC.
The Review will focus on two areas:
- how well PHARMAC performs against its current objectives and whether and how its performance against these could be improved
- whether PHARMAC’s current objectives maximise its potential to improve health outcomes for all New Zealanders as part of the wider health system, and whether and how these objectives should be changed
and will consider a range of factors, including:
- the timeliness of PHARMAC’s decision making (in particular for new medicines)
- the transparency and accessibility of decision-making processes
- equity, including access to medicines and devices for Māori and Pacific peoples.